3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
2
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Melanoma
2
Recurrence
1
Pancreatic Neoplasms
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
51
Ipilimumab
50
Cyclophosphamide
43
Nivolumab
41
aldesleukin
30
Interleukin-2
23
Vemurafenib
20
fludarabine
19
Temozolomide
18
fludarabine phosphate
15
dabrafenib
15
trametinib
12
spartalizumab
10
Radiotherapy
10
Radiosurgery
10
Dacarbazine
10
CTLA-4 Antigen
10
cobimetinib
9
binimetinib
9
poly ICLC
7
encorafenib
7
Paclitaxel
7
atezolizumab
6
Introns
6
Biopsy
6
montanide ISA 51
5
Carboplatin
5
epacadostat
4
MART-1 Antigen
4
Interferon alpha-2
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Melanoma
×
1-methyltryptophan
×
Clear all
NCT03301636
2022-09-27
NLG2107
Lumos Pharma
Phase 2
Terminated
21 enrolled
11 charts
NCT00739609
2020-05-28
D-1MT
Lumos Pharma
Phase 1
Terminated
17 enrolled